Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of breast cancer outcome with status of p53 and MDM2 SNP309.

Journal of the National Cancer Institute - 5 Jul 2006

Boersma Brenda J, Howe Tiffany M, Goodman Julie E, Yfantis Harry G, Lee Dong H, Chanock Stephen J, Ambs Stefan

Abstract excerpt

BACKGROUND: A common single-nucleotide polymorphism (SNP) in the promoter region of the MDM2 gene, known as T-309G and referred to as SNP309 for this study, leads to increased expression of Mdm2 protein and attenuated function of the p53 tumor suppressor protein. We investigated whether genetic variants in MDM2 were associated with breast cancer incidence and survival and whether the variant status could interact...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Guanine
Share to Incidence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Odds Ratio

Share to Predictive Value of Tests

Share to Proto-Oncogene Proteins c-mdm2

Share to Risk Assessment

Share to Survival Analysis

Source

Identifiers

PMID: 16818855
DOI: 10.1093/jnci/djj245

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of breast cancer outcome with status of p53 and MDM2 SNP309.PMID 16818855Read ↗

MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism.Semantic proximity Read ↗

MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.Semantic proximity Read ↗

MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer.Semantic proximity Read ↗

MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.Semantic proximity Read ↗

Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers.Semantic proximity Read ↗

MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies.Semantic proximity Read ↗

MDM2 SNP309 contributes to tumor susceptibility: a meta-analysis.Semantic proximity Read ↗

MDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis.Semantic proximity Read ↗

Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon.Semantic proximity Read ↗

Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.Semantic proximity Read ↗

Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis.Semantic proximity Read ↗

Significant Association of the MDM2 T309G Polymorphism with Breast Cancer Risk in a Turkish PopulationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.